AVELUMAB

Information current as at: 1 June 2026

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Bavencio®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Merck Healthcare Pty Ltd
Condition/indication: (therapeutic use): Renal cell carcinoma (RCC)
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: Change to listing (Minor Submission)
Comment:: --
Other PBAC consideration:: AVELUMAB

Progress Details

Submission received for:: March 2021 PBAC meeting
Opportunity for consumer comment:: Open 23/12/2020 and close 10/02/2021 (see PBS Website)
PBAC meeting:: Held on 10/03/2021
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:: Has not yet commenced
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

PBAC Public Summary Documents – March 2021

Case ID

a281

Page last updated

31 March 2026

Return to the Medicine Status Listing

v.9.19